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Abstract
Small  bowel  endoscopy  is  crucial  for  diagnosing  small  bowel  Crohn’s  disease,  and  capsule  endoscopy  is 
complemented by balloon-assisted enteroscopy to take biopsies and by magnetic resonance imaging to visualize 
enteral and extra-intestinal involvement. Recently, imaging has also become a key instrument to manage Crohn’s 
disease patients. Treatment control is advised for patients who have undergone bowel resections and is increasingly 
used to testify treatment success in non-operated patients, too. In this review we present the modern imaging methods 
to diagnose and to manage Crohn’s disease with a special focus on the small bowel. Moreover, current knowledge on 
the impact of diagnostic methods on the patients’ outcome is reported. 
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Introduction
Crohn’s disease (CD) is a chronic inflammatory intestinal disorder 
that is characterized by episodes when symptoms flare up followed by 
periods of improvement and clinical remission. The disease is lifelong 
lasting and frequently manifests in the first decades of life. Clinical 
symptoms  and  well-being  of  the  patient  is  associated  to  imaging 
findings of the mucosa and detection of inflammation seems to heavily 
impact on future prospects of the clinical course of the patient. Ongoing 
intestinal inflammation- even if subclinical-seems to be responsible 
for a debilitating course of the disease with evolvement of intestinal 
strictures and/or occurrence of malnutrition due to reduced nutrient 
uptake. This may lead to a severely reduced quality of life [1]. The small 
bowel which is involved in at least 2/3 of the patients has a key role 
in developing dismal outcome and special attention in surveillance of 
the small bowel of CD patients might therefore be of high importance. 
Several options are available for imaging the small bowel, but diagnostics 
should ideally be without objection to repeat them, easily and promptly 
to apply, and without any side effects. Most of these requirements are 
satisfied by modern diagnostic and imaging techniques. Recently, also 
the small bowel has become easier to reach by diagnostic endoscopy, 
i.e. capsule endoscopy (CE), balloon-assisted enteroscopy (BAE), and 
spiral  enteroscopy.  High-quality  cross  sectional  imaging  completes 
diagnostic armamentarium, e.g. with using percutaneous ultrasound 
and magnetic-resonance imaging (MRI) (Figure 1). 
We  review  the  modern  imaging  methods  to  diagnose  and  to 
manage CD with a special focus on small bowel CD. Moreover, current 
knowledge  on  the  impact  of  diagnostic  methods  on  the  patients’ 
outcome is reported. 
Endoscopic imaging in small bowel Crohn’s disease 
Video CE is an easy to administer and non-invasive investigation 
of the small bowel. After the passage of the intestinal tract the images 
acquired  are  reviewed  by  a  specialist.  Online  visualization  of  the 
endoscopic procedure is used to confirm passage progress but not to 
detect a lesion. To date, four small bowel CE systems are available: 
PillCam  SB2  from  Given  Imaging,  Yoqneam,  Israel  (http://www.
givenimaging.com/); EndoCapsule e.g. from Olympus Europe GmbH, 
Hamburg,  Germany,  (http://www.olympuseuropa.com/endoscopy/); 
OMOM  from  Chongqing  Jinshan  Science,  Beijing,  China,  (http://
www.cqjs.net/);  Miro-Cam  from  IntroMedic,  Seoul,  Korea  (http://
www.intromedic.com/). In the USA, only the PillCam SB2 and the 
Endo  Capsule  are  currently  approved  by  the  US  Food  and  Drug 
 
Figure 1: Crohn’s disease of the small bowel in capsule endoscopy (CE; a,b) 
and MRI (c,d). Proximal (a) and distal (b) small bowel Crohn’s disease is well 
detected by CE, and thickening of the small bowel wall is found in T2w (c) and 
contrast enhancement is seen in GRE sequence (d).Citation: Hausmann J, Albert JG (2011) Detecting and Managing Small Bowel Crohn’s Disease – Capsule Endoscopy Becoming a First Line 
Diagnostic Method? J Gastrointest Digest Sys S1:002. doi:10.4172/jgds.S1-002
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Administration, in Europe all four systems can be purchased in most 
countries. For most CE studies in CD patients the PillCam SB 2 capsule 
has been used, which consists of a CMOS-chip with a resolution of 0.1 
mm at a magnification of 1:8. Battery life is 8 h (SB 2) to about 12-16 
hours (SB 2L) (Table 1). 
For fear of capsule retention CE is usually not used in patients with 
known  intestinal  strictures  or  potential  stenosis  but  administering 
patency capsule before performing video CE, capsule retention can 
reliably be prevented [2,3]. The main limitation of the capsule is its 
inability to take biopsies or to perform interventions, the difficulty with 
which identified lesions can be accurately localized, and its inability to 
control its movement.
Balloon-assisted  enteroscopy  (BAE)  involves  push-and-pull 
maneuvers for deep intubation of the small bowel [4] and includes 
single- and double-balloon enteroscopy techniques (SBE, Olympus, 
Japan; and DBE, FujiFilm, Japan) [5]. Rate of complete small bowel 
investigations seems to be more regularly achievable using double-
balloon  rather  than  the  single-balloon  technique  whereas  the 
therapeutic impact was similar with SBE and DBE [6-8]. Complications 
are reported in less than 5% of procedures and include pancreatitis 
(<  1%),  bleeding,  and  perforation,  with  the  rate  of  complications 
increasing  in  therapeutic  interventions  [9].  Another  enteroscopy 
technique  is  the  Endo-Ease  system  (Spirus  Medical,  Stoughton, 
MA) that uses a spiral-shaped overtube to advance or withdraw the 
endoscope with rotatory clockwise and counterclockwise movements 
of the spiral [10]. Examination time might be reduced, but the insertion 
depth is minor in comparison with DBE [11,12]. With simple push-
enteroscopy even less of the small bowel may be intubated [13]. BAE 
is used to yield biopsies for histopathological examination in patients 
with  newly  detected  small  bowel  lesions  with  suspicion  of  CD  to 
exclude neoplastic or infectious disease.
Radiology in imaging small bowel Crohn’s disease 
Distension of the intestines by use of luminal contrast is essential 
to  improve  characterization  of  the  bowel  wall.  Thereby,  either  a 
sonde is inserted into the proximal small bowel (enteroclysis) or the 
luminal contrast medium is taken orally (enterography). Conventional 
fluoroscopy (small bowel follow-through and small bowel enteroclysis) 
is thereby more and more replaced by cross sectional imaging methods. 
For  both,  Computed  tomography  (CT)  and  magnetic  resonance 
imaging  (MRI),  there  have  been  enterography  and  enteroclysis 
techniques  developed  (CT-enterography/CT-enteroclysis;  CT-E  or 
MR-enterography/MR-enteroclysis;  MR-E).  Thereby,  oral  contrast 
application (enterography) provides similar quality of the images but 
improves  patient  comfort  [14-16].  Inflammatory  alterations  of  the 
small bowel and extraluminal complications such as abscess or fistula 
are equally well visualized. Lifetime radiation exposure is a concern, 
particularly in young patients [16] and doses of more than 100 mSv 
have been observed in some patients. Lack of radiation and excellent 
soft tissue contrast argue for use of MRI in CD patients and against 
fluoroscopy or CT [17-19]. 
Diagnosing small bowel Crohn’s disease: endoscopy vs. cross 
sectional imaging 
Sequence of investigations and definition of indications for small 
bowel  endoscopy  vs.  cross  sectional  imaging  is  still  under  debate 
[20]. Meta-analysis suggests higher sensitivity and optimal negative 
predictive value of endoscopic methods in comparison to radiology, 
but extraintestinal lesions are only detected by radiological imaging 
[21,22] (Table 2).
Consensus conferences cling to a diagnostic sequence in suspected 
CD to first perform ileo-colonoscopy for diagnosis of terminal ileitis 
and colitis, followed by cross sectional imaging to identify proximal 
CD  or  extra-enteric  lesions.  CE  is  regarded  a  final  identifier  of 
unexplained symptoms [20,29]. Proximal small bowel CD is best seen 
with CE, though, and detection of distal small bowel disease is equal 
sensitive with CTE, MRE, and CE suggests using CE to exclude CD in 
suspected disease cases: A pooled analysis of the results of 24 CE trails 
comprising 530 patients found that CE had a low miss rate of 0.5% for 
small bowel ulcerations, compared to 79% of other modalities (SBFT, 
push-enteroscopy, or ileo-colonoscopy) [31]. Thus, the diagnosis of 
CD can possibly most reliably be excluded with a negative CE, even if 
negative small bowel CE might not completely exclude CD – e.g. of the 
colon [32]. But, it should be remembered that any diagnostic findings 
are far from being pathognomonic, and small bowel ulcerations may 
be compatible with chronic inflammatory, neoplastic, and infectious 
origin, or might be secondary to NSAID-intake. In a cohort of patients 
who were suspected to be afflicted with small bowel CD, 37% of 102 
patients were initially diagnosed with small bowel ulcerations by CE, but 
Capsule Company Size (mm) Frame rate (Images/s) Field of view Acquisition time (hours)
PillCam SB 2 Given imaging, Israel 11 x 26 2 156° 8 (SB 2); ca. 12-16 (SB 2L) 
EndoCapsule Olympus, Japan 11 x 26 2 145° > 8
MiroCam IntroMedic, Korea  25 x 11 3 - > 11
OMOM Chongqing Jinshan Science, China 28 x 13 2 or 1 140° 8 
Table 1: Four capsule endoscopes are available at present.
Table 2: Comparison of diagnostic yield or sensitivity in cross sectional imaging techniques and in endoscopy in diagnosing small bowel Crohn’s disease; CTE – computed 
tomography enterography; MRI – magnetic resonance imaging; CE – Capsule endoscopy.
Author  N  Capsule endoscopy  Cross sectional imaging  Statistical significance 
Eliakim [23]  2004  CTE  35  77%  20%  p <0.05 
Voderholzer [24]  2005  CTE  41  25/41 (61%)  12/41 (29%)  p=0.004 
Hara [25]  2006  CT  17  12/17 (71%)  9/17 (53%)  n.s. 
Solem [26]  2008  CTE  28  83%  67%  n.s. 
Albert [27]  2005  MRI  52  25/27 (93%)  21/27 (78%)  n.s. 
Tillack [51]  2008  MRI 19 18/19 (95%) 18/19 (95%)  n.s.
Böcker [30]  2011 MRI 21 9/21 (43%) 6/21 (29%) Proximal small bowel
Jensen [14]
Casciani [52]
2011 
2011 
MRI and CTE 
MRI 
93 
37 
100% 
10/11 (91%) 
81 % (MRI) 
76% (CTE) 
19/19 (100%) 
Proximal small bowel 
n.s. Citation: Hausmann J, Albert JG (2011) Detecting and Managing Small Bowel Crohn’s Disease – Capsule Endoscopy Becoming a First Line 
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only 13% had the diagnosis of CD maintained at one year of follow-up 
[33]. Even if some features of small bowel lesions might rather suggest 
CD (irregular and longitudinal ulcerations, multiple locations, cobble 
stone aspect of the small bowel) than NSAID use (circular ulcerations, 
webs)  or  neoplasia  (circumscribed  lesion),  these  identifier  must  be 
interpreted very cautious before labeling a patient to be affected by CD. 
In established CD, immediate access to cross sectional imaging (e.g. 
MRI) is important in many clinical scenarios such as the septic patient, 
or in ileus, and severe intestinal inflammation, suppurative disease, and 
conglomerate tumor or fistulae can be detected. Endoscopy is necessary 
to discriminate inflammatory from chronic, non-inflammatory lesions 
or strictures. In the unclassified type of inflammatory bowel disease 
(IBDU) it may be reasonable to screen for small bowel involvement 
to confirm the diagnosis of CD in some patients. In one study, the 
diagnosis  of  IBDU  had  been  revised  and  changed  to  CD  in  15  % 
of  120  patients  [34,32]  but  minor  findings  should  not  mislead  to 
revise the diagnosis [35]. Postoperatively endoscopic surveillance is 
recommended [30] and inflammatory lesions are best discriminated 
from non-inflammatory bowel alterations by use of endoscopy. Hereby, 
CE might replace ileo-colonoscopy to detect recurrence, as accuracy of 
CE is similar to conventional colonoscopy in the anastomotic region, 
but proximal disease is exclusively visualized by CE [36,37].
Outcome in terms of mucosal healing 
Endoscopy has been used to detect CD activity in the postoperative 
situation,  i.e.  in  a  high-risk  group  of  patients  who  were  prone  to 
undergo a complicated disease course with high probability to be in 
need of further surgery. In this patient group, the future course of the 
disease was best predicted by the severity of the early postoperative 
lesions, as observed at ileo-colonoscopy [38]. Since then, endoscopic 
treatment control in the postoperative patient group is well established 
with  endoscopy  being  the  golden  standard  of  surveillance  [38]. 
Endoscopy  has  increasingly  been  used  to  document  on  mucosal 
healing in CD patients and in ulcerative colitis, and mucosal healing 
has more and more been established as an important sign of treatment 
efficacy  and  a  reliable  prognostic  marker,  table  3.  Mucosal  healing 
has been described in CD patients who were on Azathioprine and 
who experienced complete healing of their colitis that was confirmed 
by  disappearance  of  the  inflammatory  infiltrate  in  histopathologic 
examination [39]. Mucosal healing as documented by endoscopy after 
1 year of treatment has been found to predict reduced subsequent 
disease activity over the following five years and decreased need for 
active treatment [40]. Recently, complete mucosal healing was found 
to be associated with a sustained, steroid-free remission in early-stage 
Crohn’s disease [41]. Thereby, endoscopic monitoring the treatment 
has been shown ideal to identify those patients that are at high-risk of a 
dismal outcome: At 3 months from the start of IFX therapy, endoscopic 
investigations correctly predicted responders of maintenance therapy 
in active luminal CD [42]. Moreover, mucosal healing was associated 
with  an  improved  long-term  outcome  with  lesser  need  for  major 
abdominal surgeries [43] (Table 3). 
Today, endoscopic surveillance is used to assess disease activity 
and  mucosal  healing  in  patients  with  persistent  symptoms  despite 
therapy and when treatment discontinuation is considered. Regular, 
scheduled screening endoscopies are not established. Ileocolonoscopy 
is the standard procedure in use, even if CE or colon CE could be used 
to visualize both, the small and the large intestines. Thus, a recent study 
demonstrated that the findings of CE had a serious impact on clinical 
practice with a change of management in 50% of the patients with 
established or suspected CD [50].
Conclusion 
Small bowel endoscopy is crucial for diagnosing small bowel CD, 
and  CE  is  complemented  by  BAE  to  take  biopsies  and  by  MRI  to 
visualize enteral and extra-intestinal involvement. Recently, imaging 
has also become a key instrument to manage CD patients. Treatment 
control is advised for patients who have undergone bowel resections 
and is increasingly used to testify treatment success in non-operated 
patients, too. Recent studies have illustrated the higher sensitivity of CE 
to detect small bowel lesions in comparison to radiology and clinical 
impact  of  the  findings  has  been  demonstrated.  Further  studies  are 
needed to evaluate the exact clinical role of small bowel CE, colonic 
CE, and maybe pan-intestinal CE in the management of CD.
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